We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Health sector stocks fluctuate amid DOJ probe into UnitedHealth (UNH), Gilead upgrade for HIV treatments, and Moderna's focus on non-COVID approvals.
MarketBeat on MSN1d
Gilead Sciences: 4 Reasons This Stock Has Much More To RiseCompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...
Join the live Q&A on PrEP, the latest in HIV prevention. Text your questions to 713-526-1111 and tune in Monday to learn ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
A new HIV drug, lenacapavir, appears highly effective against strains circulating in Uganda, according to a study led by ...
Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...
We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at ...
Below, check out the roundup of California Healthline's coverage. For today's national health news, read KFF Health News' Morning Briefing.
A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback